Breast Cancer Clinical Trials

⁃ Patients are eligible to be included in the study only if all the following criteria apply:

⁃ Disease Characteristics

• Patients with any of the following disease characteristics are eligible (specific population subject to FDA Dato-DXd label):

• • Patients with unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior ET and chemotherapy for unresectable or metastatic disease.

• OR

• • Adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Participants will be enrolled upon FDA approval on use of Dato-DXd for this indication.

• OR

• • Patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.

• Age

• Patient must be ≥ 18 years, at the time of signing the informed consent.

• Type of Patient and Disease Characteristics-

• Has documentation that Dato-DXd will be prescribed for the labelled indication and has not received any dose of Dato-DXd prior to enrollment.

• Is willing to comply with use of prophylactic dexamethasone mouthwash at the start of first infusion and throughout Dato-DXd administration.

• ECOG performance status 0 or 1.

• Has adequate bone marrow function (hemoglobin ≥ 9 g/dL; red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).

• All women of childbearing potential must have a negative serum pregnancy test result at screening.

• Informed Consent

• Capable of giving signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the ICF and the protocol.